and speculative discussion which tends to surround the "beta blockade withdrawal syndrome", confining our conclusions to the specific agent and clinical setting tested. If it can ever be considered reasonable to withdraw a beta blocker then based on our data in patients with severe stable angina it should surely not be considered a "dangerous" practice to stop treatment with atenolol in patients who have mild or no symptoms?

P R Walker,
Department of Cardiology,
Bristol Royal Infirmary,
Bristol BS2 8HW.

References

- 1 Meinertz T, Just H, Kasper W, Kersting F, Breuing

Effect of timolol on changes in serum potassium concentration during acute myocardial infarction

Sir,
Nordrehaug *et al* (1985; 53: 388-93) showed that the administration of timolol after myocardial infarction reduces the frequency of hypokalaemia during the first 24 hours after the infarct. For greater accuracy they should have used plasma rather than serum because there is erratic leakage from erythrocytes during coagulation.

Using insulin-induced hypoglycaemia (in healthy volunteers) as another model for acute stress, we have also observed that prior non-specific beta blockade with nadolol or propranolol prevents hypokalaemia.^{1,2} Since these effects of stress are mediated through a pronounced increase in plasma catecholamine concentrations it is pertinent to mention that adrenaline-induced influx of potassium into leucocytes in vitro is inhibited by the non-selective beta blocker, timolol and that these cells are probably a model for body cells as a whole.³ In addition, beta blockade in the hypoglycaemia model¹ reduces the magnitude of (a) increase in serum free fatty acid concentrations by inhibiting lipolysis; (b) the increase in various haemostatic variables like factor VIII related antigen; (c) platelet aggregation. These effects are related to the pathogenesis of myocardial infarction since they are all arrhythmogenic or prothrombotic.⁴⁻⁶ It is also important to determine whether selective blockade of beta₁ receptors produces similar results since some of the above effects of catecholamines are thought to be mainly mediated by beta₂ receptors.

K-H. β -blocker withdrawal syndrome? *Lancet* 1979; i: 270.

- 2 Alderman EL, Coltart DJ, Wettach GE, Harrison DC. Coronary artery syndromes after sudden propranolol withdrawal. *Ann Intern Med* 1974; 81: 625-7.
- 3 Diaz RG, Somberg JC, Freeman E, Levitt B. Withdrawal of propranolol and myocardial infarction [Letter]. *Lancet* 1973; i: 1068.
- 4 Slome R. Withdrawal of propranolol and myocardial infarction [Letter]. *Lancet* 1973; i: 156.
- 5 Mizgala HF, Counsell J. Acute coronary syndromes following abrupt cessation of oral propranolol therapy. *Can Med Assoc J* 1976; 114: 1123-6.
- 6 Nattel S, Rangno RE, Loon GV. Mechanism of propranolol withdrawal phenomena. *Circulation* 1976; 59: 1158-64.
- 7 Ross PJ, Lewis MJ, Sheridan DJ, Henderson AH. Adrenergic hypersensitivity after beta-blocker withdrawal. *Br Heart J* 1981; 45: 637-42.
- 8 Shand DG, Wood AJJ. Propranolol withdrawal syndrome—why? *Circulation* 1978; 58: 202-3.

D P Mikhailidis,
P Dandona,
D N Baron,
Department of Chemical Pathology and Human Metabolism,
Royal Free Hospital and School of Medicine,
London NW3 2QG.

References

- 1 Mikhailidis DP, Barradas MA, Hutton RA, Jeremy JY, Sabur M, Dandona P. The effect of non-specific β -blockade on metabolic and haemostatic variables during hypoglycaemia. *Diabetes Research* 1985; 2: 127-34.
- 2 Mikhailidis DP, Dandona P. Adrenaline and potassium. *Lancet* 1984; i: 170.
- 3 Baron DN, Green RJ, Khan FA. Adrenaline and ion flux in isolated human leucocytes. *Clin Sci* 1985; 68: 517-21.
- 4 Tansey MJB, Opie LH. Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction. *Lancet* 1983; ii: 419-22.
- 5 Jeremy JY, Mikhailidis DP, Dandona P. Simulating the diabetic environment modifies in vitro prostacyclin synthesis. *Diabetes* 1983; 32: 217-21.
- 6 Mikhailidis DP, Mikhailidis AM, Barradas MA, Dandona P. Effect of non-esterified fatty acids on the stability of prostacyclin activity. *Metabolism* 1983; 32: 717-21.